ShanghaiTech University Knowledge Management System
| Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds | |
| 2017-01-26 | |
| Source Publication | FRONTIERS IN IMMUNOLOGY
 |
| ISSN | 1664-3224 |
| Volume | 8 |
| Status | 已发表 |
| DOI | 10.3389/fimmu.2017.00038 |
| Abstract | Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells (T cell, natural killer cell, or macrophage cell) toward target cells have shown great potential to maximize the benefits of antibody therapy. In the past decade, many novel concepts to generate bispecific and multispecific antibodies have evolved successfully into a range of formats from full bispecific immunoglobulin gammas to antibody fragments. Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells. Promisingly, crystallizable fragment (Fc) antigen-binding fragment and monomeric antibody or half antibody may be particularly advantageous to target solid tumors owing to their small size and thus good tissue penetration potential while, on the other hand, keeping Fc-related effector functions such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis, and extended serum half-life via interaction with neonatal Fc receptor. This review, therefore, focuses on the progress of Fc engineering in generating bispecific molecules and on the use of small antibody fragment as scaffolds for therapeutic development. |
| Keyword | mAbs Fc region FcRn bispecific monovalent heterodimer monomeric Fc Fc antigen-binding |
| Indexed By | SCI |
| Language | 英语 |
| Funding Project | National Natural Science Foundation of China[81572698] |
| WOS Research Area | Immunology |
| WOS Subject | Immunology |
| WOS ID | WOS:000392744600001 |
| Publisher | FRONTIERS MEDIA SA |
| WOS Keyword | NATURAL-KILLER-CELLS ; MONOMERIC IGG1 FC ; SINGLE HUMAN CD4 ; ANTIGEN-BINDING ; IN-VIVO ; HIV-1 INHIBITORS ; FRAGMENT FCAB ; LIGHT-CHAIN ; GAMMA-RI ; ANTI-CD30/CD16A ANTIBODY |
| Original Document Type | Review |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/1529 |
| Collection | 免疫化学研究所_特聘教授组_抗体工程学实验室 免疫化学研究所_特聘教授组_功能筛选实验室 |
| Corresponding Author | Sidhu, Sachdev S.; Wu, Donghui |
| Affiliation | 1.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Lab Antibody Engn, Shanghai, Peoples R China 2.Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Banting & Best Dept Med Res, Toronto, ON, Canada 3.Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Mol Genet, Toronto, ON, Canada |
| First Author Affilication | Shanghai Institute for Advanced Immunochemical Studies |
| Corresponding Author Affilication | Shanghai Institute for Advanced Immunochemical Studies |
| First Signature Affilication | Shanghai Institute for Advanced Immunochemical Studies |
| Recommended Citation GB/T 7714 | Liu, Hongyan,Saxena, Abhishek,Sidhu, Sachdev S.,et al. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds[J]. FRONTIERS IN IMMUNOLOGY,2017,8. |
| APA | Liu, Hongyan,Saxena, Abhishek,Sidhu, Sachdev S.,&Wu, Donghui.(2017).Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.FRONTIERS IN IMMUNOLOGY,8. |
| MLA | Liu, Hongyan,et al."Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds".FRONTIERS IN IMMUNOLOGY 8(2017). |
| Files in This Item: | Download All | |||||
| File Name/Size | DocType | Version | Access | License | ||
Edit Comment
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.